In 2021 and 2022, two immune checkpoint inhibitors received FDA approval in the
neoadjuvant setting for the treatment of early-stage triple negative breast cancer (TNBC) and …

Breast cancer is the leading cause of cancer-related death among women globally.
Immunotherapy has emerged as a major milestone in contemporary oncology. This study …

Background: As a highly prevalent malignancy among women worldwide, breast cancer,
remains a critical public health issue necessitating the development of novel therapeutics …

Circulating miRNAs (cirmiRNAs) can be packaged into the exosomes, participating in
intercellular communication, which affects the malignant progression and therapy resistance …

Triple-negative breast cancer (TNBC) is known for its poor prognosis and aggressive
behavior, being highly prone to recurrence and metastasis, and currently has limited …

Due to the immunosuppressive tumor microenvironment (TME) and potential systemic
toxicity, chemotherapy often fails to elicit satisfactory anti-tumor responses, so how to …

Immune exclusion inhibits anti-tumor immunity and response to immunotherapy, but its
mechanisms remain poorly defined. Here, we demonstrate that Trophoblast Cell-Surface …

Breast cancer, a multifaceted and heterogeneous malady, invites scrutiny into its
microscopic intricacies, where the landscape of cellular interactions orchestrates disease …

Due to the tumor immunosuppressive microenvironment and potential systemic toxicity,
chemotherapy often fails to trigger satisfactory anti-tumor results, so how to activate anti …

The tertiary lymphoid structure (TLS) is considered a potential prognosis factor for breast
cancer, and it has a high correlation with the response of immune therapy. Inducing TLS …